| This article has been cited by |
| 1 | Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation | |
| Sazlyna Mohd Sazlly Lim,Fekade Bruck Sime,Jason A. Roberts |
| International Journal of Antimicrobial Agents.2019;53(6)726 |
| [DOI] |
|
| 2 | Treatment of Infections by OXA-48-Producing Enterobacteriaceae | |
| Adam Stewart,Patrick Harris,Andrew Henderson,David Paterson |
| Antimicrobial Agents and Chemotherapy.2018;62(11)726 |
| [DOI] |
|
| 3 | Potent ß-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates | |
| Bartolome Moya,Isabel M. Barcelo,Sachin Bhagwat,Mahesh Patel,German Bou,Krisztina M. Papp-Wallace,Robert A. Bonomo,Antonio Oliver |
| Antimicrobial Agents and Chemotherapy.2017;61(11)726 |
| [DOI] |
|
| 4 | Intravenous polymyxins: Revival with puzzle | |
| Yun Yu,Aihua Fei,Zengbin Wu,Chengjin Gao,Shuming Pan |
| BioScience Trends.2017;11(4)370 |
| [DOI] |
|
| 5 | Treatment of patients with serious infections due to carbapenem-resistantAcinetobacter baumannii: How viable are the current options? | |
| J. Nicholas O'Donnell,Vibert Putra,Thomas P. Lodise |
| Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2021;41(9)762 |
| [DOI] |
|
| 6 | Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions | |
| Matteo Bassetti,Antonio Vena,Daniele Roberto Giacobbe,Nadia Castaldo |
| Archives of Medical Research.2021;52(8)817 |
| [DOI] |
|
